US LNG exports surge but will buyers in China turn up?
Rajeev Singh, the Chief Executive Officer of Accolade, Inc. (NASDAQ:ACCD), recently sold a portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Singh sold 1,121 shares of Accolade common stock on March 4, 2025, at a price of $6.96 per share, totaling $7,802. This transaction was conducted to cover tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs). The sale comes as Accolade’s stock has shown remarkable strength, with a 103% gain year-to-date according to InvestingPro data.
In addition to the sale, Singh acquired 3,786 shares of common stock on March 3, 2025, through the conversion of RSUs, without any cash exchange. Following these transactions, Singh holds 828,408 shares directly and 651,619 shares indirectly through Avanti Holdings, LLC, where he has voting and investment power. InvestingPro analysis indicates the company is currently undervalued, with strong liquidity metrics and a current ratio of 2.63. Discover more insights and 7 additional ProTips with an InvestingPro subscription, including detailed analysis in the comprehensive Pro Research Report.
In other recent news, Accolade Inc . announced its acquisition by Transcarent in a deal valued at $621 million, with shareholders receiving $7.03 per share. This acquisition, expected to finalize in the second quarter of 2025, represents a significant premium over Accolade’s prior stock price. Following the announcement, Raymond (NSE:RYMD) James downgraded Accolade’s stock rating from Outperform to Market Perform, reflecting adjustments based on fiscal year 2026 estimates. Meanwhile, Truist Securities maintained a Buy rating on Accolade, reiterating a price target of $7.50, citing the merger’s potential to enhance the company’s market position. Stifel also downgraded Accolade’s stock from Buy to Hold, adjusting the price target to $7.03, reflecting a cautious stance on potential competing bids. The merger combines Accolade’s health solutions with Transcarent’s offerings, serving over 1,400 clients and creating cross-selling opportunities. The integration is anticipated to streamline digital health solutions and improve client relationships. Accolade has withdrawn its financial guidance for the fiscal year but plans to report its third-quarter results within the previously provided range.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.